Health
FDA Approves First Treatment for MCT8 Deficiency
Source: U.S. Food and Drug Administration (FDA)
Published:
Source summary — U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient
This page reports what the publisher stated. MYITEDU has not independently verified these claims.
Read the original article — U.S. Food and Drug Administration (FDA) ↗
Attribution: Source: U.S. Food and Drug Administration (fda.gov)
Share
Instagram does not support sharing links from websites. Download the card, post it from the Instagram app and paste the caption.
Report a correction
Tell us about an error in this item, its translation, date or attribution. Your contact details stay private and are used only to follow up.